- Home
- IMCR vs EVCM Comparison
IMCR vs EVCM Comparison
Compare IMCR & EVCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- EVCM
- Stock Information
- Founded
- IMCR 2008
- EVCM 2006
- Country
- IMCR United Kingdom
- EVCM United States
- Employees
- IMCR N/A
- EVCM N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- EVCM EDP Services
- Sector
- IMCR Health Care
- EVCM Technology
- Exchange
- IMCR Nasdaq
- EVCM Nasdaq
- Market Cap
- IMCR 1.6B
- EVCM 1.7B
- IPO Year
- IMCR 2021
- EVCM 2021
- Fundamental
- Price
- IMCR $35.00
- EVCM $10.65
- Analyst Decision
- IMCR Buy
- EVCM Buy
- Analyst Count
- IMCR 10
- EVCM 12
- Target Price
- IMCR $58.13
- EVCM $11.67
- AVG Volume (30 Days)
- IMCR 383.2K
- EVCM 255.6K
- Earning Date
- IMCR 08-07-2025
- EVCM 08-05-2025
- Dividend Yield
- IMCR N/A
- EVCM N/A
- EPS Growth
- IMCR N/A
- EVCM N/A
- EPS
- IMCR N/A
- EVCM N/A
- Revenue
- IMCR $333,581,000.00
- EVCM $703,186,000.00
- Revenue This Year
- IMCR $26.82
- EVCM N/A
- Revenue Next Year
- IMCR $8.15
- EVCM $6.31
- P/E Ratio
- IMCR N/A
- EVCM N/A
- Revenue Growth
- IMCR 25.75
- EVCM 7.84
- 52 Week Low
- IMCR $23.15
- EVCM $8.10
- 52 Week High
- IMCR $41.54
- EVCM $12.35
- Technical
- Relative Strength Index (RSI)
- IMCR 59.78
- EVCM 58.09
- Support Level
- IMCR $32.20
- EVCM $10.53
- Resistance Level
- IMCR $35.75
- EVCM $10.88
- Average True Range (ATR)
- IMCR 1.31
- EVCM 0.30
- MACD
- IMCR 0.28
- EVCM 0.06
- Stochastic Oscillator
- IMCR 84.94
- EVCM 79.67
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About EVCM EverCommerce Inc.
EverCommerce Inc provides tailored Software-as-a-Service solutions for service-based small- and medium-sized businesses (SMBs) in-home services, health services, and fitness & wellness. With a platform serving approximately 708,000 customers across three core verticals, including numerous micro-verticals, their solutions address diverse needs within these sectors. Revenue is primarily generated from the United States. Operating in a single segment, their vertically-tailored SaaS offerings cater to SMBs' specialized demands, enabling them to automate processes, generate business, and enhance customer loyalty. The majority of customers contribute modest revenue, with a small percentage contributing higher amounts.